Abstract：
UNASSIGNED: Spinal cord injury (SCI) presents significant challenges due to its debilitating nature and potential complications. While few medications have shown efficacy in improving neurological recovery, 4-Aminopyridine (4-AP), a voltage-gated potassium channel blocker, has been used clinically off-label to improve neurologic function in adults with spinal cord-related paralysis. However, evidence regarding its safety and effectiveness in the pediatric population remains scarce, as it is approved for use in older patients.
UNASSIGNED: This manuscript reports the case of a pediatric patient who sustained a traumatic cervical SCI. Initial neurological assessment indicated a C1 motor complete SCI. Surgical intervention for bullet removal and spinal fusion was carried out, followed by comprehensive inpatient rehabilitation.
UNASSIGNED: 4-AP was introduced three months post-injury and was well-tolerated without obvious adverse effects. Notably, he exhibited neurological and functional improvement after four months of 4-AP use, though his improvement followed the expected trajectory of recovery. To date, this case represents the first case of 4-AP administration in a pediatric SCI patient, and therefore these findings contribute valuable clinical insight. By documenting the clinical trajectory of this case, this manuscript suggests 4-AP may be safe for use in pediatric patients.
UNASSIGNED: This manuscript reports the case of a pediatric patient who sustained a traumatic cervical SCI. Initial neurological assessment indicated a C1 motor complete SCI. Surgical intervention for bullet removal and spinal fusion was carried out, followed by comprehensive inpatient rehabilitation.
UNASSIGNED: 4-AP was introduced three months post-injury and was well-tolerated without obvious adverse effects. Notably, he exhibited neurological and functional improvement after four months of 4-AP use, though his improvement followed the expected trajectory of recovery. To date, this case represents the first case of 4-AP administration in a pediatric SCI patient, and therefore these findings contribute valuable clinical insight. By documenting the clinical trajectory of this case, this manuscript suggests 4-AP may be safe for use in pediatric patients.
摘要：
■脊髓损伤（SCI）由于其衰弱的性质和潜在的并发症而提出了重大挑战。虽然很少有药物显示出改善神经系统恢复的功效，4-氨基吡啶(4-AP),电压门控钾通道阻断剂,已在临床上用于改善患有脊髓相关瘫痪的成年人的神经功能。然而,关于其在儿科人群中的安全性和有效性的证据仍然很少，因为它被批准用于老年患者。
■本手稿报道了一名儿童患者的病例，该患者遭受了颈椎脊髓损伤。最初的神经学评估表明C1运动完全SCI。进行了子弹切除和脊柱融合的手术干预，其次是全面的住院康复。
■4-AP在受伤后三个月引入，耐受性良好，无明显不良反应。值得注意的是,使用4-AP4个月后，他表现出神经和功能改善，尽管他的进步遵循了预期的复苏轨迹。迄今为止,该病例代表儿科SCI患者中4-AP给药的第一例，因此，这些发现有助于有价值的临床见解。通过记录这个病例的临床轨迹,这篇手稿提示4-AP在儿科患者中使用可能是安全的.
■本手稿报道了一名儿童患者的病例，该患者遭受了颈椎脊髓损伤。最初的神经学评估表明C1运动完全SCI。进行了子弹切除和脊柱融合的手术干预，其次是全面的住院康复。
■4-AP在受伤后三个月引入，耐受性良好，无明显不良反应。值得注意的是,使用4-AP4个月后，他表现出神经和功能改善，尽管他的进步遵循了预期的复苏轨迹。迄今为止,该病例代表儿科SCI患者中4-AP给药的第一例，因此，这些发现有助于有价值的临床见解。通过记录这个病例的临床轨迹,这篇手稿提示4-AP在儿科患者中使用可能是安全的.
